Arbutus reduces headcount after axing HBV combo trial that features Imfinzi

Ar­bu­tus plans to lay off 40% of its staff af­ter end­ing one of three on­go­ing mid­stage he­pati­tis B tri­als.

The de­ci­sion to cut the study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.